- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04069156
The ARIES HeartMate 3 Pump IDE Study
December 13, 2023 updated by: Abbott Medical Devices
Antiplatelet Removal and HemocompatIbility EventS With the HeartMate 3 Pump IDE Study
Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This clinical investigation is a prospective, randomized, double-blinded, placebo-controlled study of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo.
Study Type
Interventional
Enrollment (Actual)
628
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New
-
Darlinghurst, New, Australia, 2010
- St. Vincent's Hospital, Sydney
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- The Alfred Hospital
-
-
-
-
-
Vienna, Austria, 1090
- AKH - Wien
-
-
-
-
-
Edmonton, Canada, T6G 2B7
- University of Alberta Hospital
-
-
-
-
Central Bohemia
-
Prague, Central Bohemia, Czechia, 140 24
- IKEM Prague
-
-
-
-
-
Pessac, France, 33600
- Hôpital Haut Lévêque
-
Toulouse, France, 31000
- CHU Rangueil Toulouse
-
-
-
-
-
Milan, Italy
- Ospedale San Raffaele
-
-
-
-
-
Astana, Kazakhstan, 10000
- National Research Center for Cardiac Surgery
-
-
-
-
-
Birmingham, United Kingdom, B15 2GW
- Queen Elizabeth Hospital
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Baptist Health Medical Center
-
-
California
-
La Jolla, California, United States, 92037
- University of California, San Diego
-
Palo Alto, California, United States, 94304
- Stanford University Medical Center
-
San Diego, California, United States, 92123
- Sharp Memorial Hospital
-
San Francisco, California, United States, 94109
- California Pacific Medical Center - Van Ness Campus
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Hospital
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washington Hospital Center
-
-
Florida
-
Miami, Florida, United States, 33136
- Miami Transplant Institute - Jackson Memorial
-
Orlando, Florida, United States, 32804
- AdventHealth Orlando
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University Hospital
-
Atlanta, Georgia, United States, 30309
- Piedmont Heart Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
Oak Lawn, Illinois, United States, 60453
- Advocate Christ Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46240
- St. Vincent Hospital
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Kansas University Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02115
- Brigham & Women's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Minneapolis Heart Institute
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Medical Center Fairview
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
New York, New York, United States, 10032
- New York-Presbyterian/Columbia University Medical Center
-
New York, New York, United States, 10467
- Montefiore Medical Center - Moses Division
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill
-
Charlotte, North Carolina, United States, 28203
- Carolinas Medical Center
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The Christ Hospital
-
Cleveland, Ohio, United States, 44195
- The Cleveland Clinic Foundation
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- INTEGRIS Baptist Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97225
- Providence Heart & Vascular Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center
-
Pittsburgh, Pennsylvania, United States, 15212
- Allegheny General Hospital - ASRI
-
-
Texas
-
Dallas, Texas, United States, 75246
- Baylor University Hospital
-
Houston, Texas, United States, 77030
- Memorial Hermann Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53215
- Aurora Medical Group
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject will receive the HeartMate 3 per standard of care (SOC) in accordance with the approved indications for use in the country of implant.
- Subject will receive the HeartMate 3 as their first durable VAD.
- Subject must provide written informed consent prior to any clinical investigation related procedure.
- In female patients of child bearing capability, subject will not be currently pregnant or breastfeeding and on appropriate contraception.
Exclusion Criteria:
- Post-implant additional temporary or permanent mechanical circulatory support (MCS).
- Investigator mandated antiplatelet therapy for other conditions (including mandated presence or absence of antiplatelet agent).
- Patients who are nil per os (NPO) post-implant through day 7.
- Subjects with a known allergy to acetylsalicylic acid (aspirin).
- Participation in any other clinical investigation(s) involving an MCS device, or interventional investigation(s) likely to confound study results or affect study outcome.
- Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Arm
LVAD Patients on the placebo arm will be given placebo medication
|
Subjects will undergo Heartmate 3 LVAD implant prior to randomization
Subjects will be randomized to either Placebo or Aspirin post implant
|
Active Comparator: Active Arm
LVAD Patients on the active arm will be given 100mg Aspirin
|
Subjects will undergo Heartmate 3 LVAD implant prior to randomization
Subjects will be randomized to either Placebo or Aspirin post implant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Non-Inferiority Primary Endpoint
Time Frame: 1 year post implant
|
The primary endpoint for this study will be met if the placebo arm is non-inferior to the aspirin arm in the composite of survival free of any non-surgical (any event occuring > 14 days post implant) major hemocompatibility related adverse event (Stroke, pump thrombosis, bleeding [intracranial bleeds that do not meet stroke definition], arterial peripheral thromboembolism), at 1-year post implant
|
1 year post implant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Non-surgical Major Hemorrhagic Events
Time Frame: Up to 3 years post implant
|
The non-surgical major hemorrhagic events will be compared between the two arms of the study.
|
Up to 3 years post implant
|
Rate of Non-surgical Major Thrombotic Events
Time Frame: Up to 3 years post implant
|
The non-surgical major thrombotic events will be compared between the two arms of the study.
|
Up to 3 years post implant
|
Rate of Survival
Time Frame: Up to 3 years post implant
|
Survival will be compared between the two arms of the study.
|
Up to 3 years post implant
|
Rate of Stroke Rates
Time Frame: Up to 3 years post implant
|
Stroke rates will be compared between the two arms of the study.
|
Up to 3 years post implant
|
Rate of Pump Thrombosis Rates
Time Frame: Up to 3 years post implant
|
Pump thrombosis rates will be compared between the two arms of the study.
|
Up to 3 years post implant
|
Rate of Bleeding Rates
Time Frame: Up to 3 years post implant
|
Bleeding rates will be compared between the two arms of the study.
|
Up to 3 years post implant
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Hemocompatibility Score (HCS)
Time Frame: Up to 3 years post implant
|
This study will also assess changes in the hemocompatibility score as a result of removal of antiplatelet therapy from the antithrombotic regimen
|
Up to 3 years post implant
|
Rate of Rehospitalization
Time Frame: Up to 3 years post implant
|
This study will also assess changes in the rehospitalization as a result of removal of antiplatelet therapy from the antithrombotic regimen
|
Up to 3 years post implant
|
Economic Cost Implications
Time Frame: Up to 3 years post implant
|
This study will also assess changes in the cost implications as a result of removal of antiplatelet therapy from the antithrombotic regimen
|
Up to 3 years post implant
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 14, 2020
Primary Completion (Actual)
August 10, 2023
Study Completion (Actual)
August 10, 2023
Study Registration Dates
First Submitted
August 21, 2019
First Submitted That Met QC Criteria
August 23, 2019
First Posted (Actual)
August 28, 2019
Study Record Updates
Last Update Posted (Estimated)
December 15, 2023
Last Update Submitted That Met QC Criteria
December 13, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- ABT-CIP-10305
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
To be determined
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on LVAD Implant
-
University of Colorado, DenverCompletedVentricular Dysfunction, LeftUnited States
-
University of FloridaCompletedHeart FailureUnited States
-
Baylor College of MedicinePatient-Centered Outcomes Research Institute; M.D. Anderson Cancer Center; The... and other collaboratorsCompletedEnd-Stage Heart Failure | Bridge-to-Transplant LVAD Placement (BTT) | Destination Therapy LVAD Placement (DT) | Refusal of LVAD Placement (Decliners) | LVAD CaregiversUnited States
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHeart Failure, CongestiveUnited States
-
University of Southern CaliforniaActive, not recruiting
-
Hannover Medical SchoolWithdrawnHeart Failure | Pulmonary Hypertension | Heart Failure With Reduced Ejection Fraction | Heart Failure With Normal Ejection FractionGermany
-
University of Colorado, DenverPatient-Centered Outcomes Research InstituteCompletedHeart Failure | Heart-assist DevicesUnited States
-
Medtronic Cardiac Rhythm and Heart FailureCompletedChronic Heart FailureUnited States
-
STAVROS G DRAKOSAmerican Heart AssociationRecruiting
-
Terumo Heart Inc.TerminatedHeart FailureUnited States, Canada